Disease Targets

The Problem: Hospitals struggle to know which sepsis patients will relapse.

The GNOMX solution:

GNOMX is developing ReAdmitPredict, an innovative epigenetic AI test to predict sepsis hospital readmission risk, addressing a $3.5 billion annual challenge for the U.S. healthcare system. With nearly 40% of sepsis patients facing readmission within 90 days, our immune dysregulation host-based assay provides vital predictive insights 24-48 hours prior to discharge. Identifying high-risk readmission patients can improve discharge decisions, follow-up plans, patient outcomes, and decrease readmission rates and costs. This project is currently accelerated by a Phase 1 BARDA DRIVE contract.

The Problem: A 3-Week Diagnostic Blind Spot

Current FDA-cleared 2-tiered serology tests are unreliable during the first 2–3 weeks of infection. Because these tests rely on the body's antibody response—which takes time to develop—their sensitivity is less than 50% during the acute phase. This often leads to missed diagnoses and delayed treatment.

The GNOMX Solution: LymeScreen Dx, a

 host-based epigenetic AI blood test designed to identify acute Lyme disease within those first two critical weeks. By analyzing the body’s immediate cellular response rather than waiting for antibodies, LymeScreen Dx provides:

• Higher Sensitivity: Detecting infection when traditional tests fail.
• Early Intervention: Enabling faster treatment to improve clinical outcomes.

Current Progress & Partnerships

HHS LymeX Award: GNOMX was recently awarded a subcontract by the HHS LymeX NASA partnership to accelerate the development of this acute Lyme disease test.

Development Stage: We are currently finalizing the development and analytical verification of our PCR-based assay into a Laboratory Developed Test (LDT) for clinical use.